The Dermatology Digest

MARCH 10, 2025

Th e Phase 3b, randomized, double-blind, placebo-controlled clinical trial included 99 patients with moderate-to-severe plaque psoriasis. ” The safety profile was consistent with the known safety profile of tildrakizumab, and no serious adverse events related to ILUMYA treatment occurred in this clinical trial,the study showed. .

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

AAAMS

DECEMBER 19, 2024

Whether you’re a physician, nurse, or other medical professional, entering this lucrative field allows you to combine your medical expertise with artistry to help patients look and feel their best. Understanding patient safety protocols and treatment planning. Why Choose a Career in Aesthetic Medicine?

Social Media 52

Social Media Work-Life Balance Training Microneedling 52

The Dermatology Digest

MARCH 8, 2025

The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% All you need is chronic itch for six weeks or longer, nodules, pustules, excoriation, and scratching; You dont need a biopsy as that can confuse the clinical picture.

Safety 36

Safety Clinic Therapy Dermatology 36

The Dermatology Digest

DECEMBER 4, 2024

Restem’s ULSC therapy has shown promising results in early clinical trials, demonstrating safety, tolerability and initial clinically significant improvements, as well as the potential to significantly reduce the need for steroid use in patients.

Treatments 36

Treatments Office Therapy Clinic 36

The Dermatology Digest

MARCH 9, 2025

The safety and efficacy of dupilumab in BP are currently under clinical investigation and have not been evaluated by any regulatory authority. Sustained disease remission was defined as complete clinical remission with completion of OCS taper by week 16 without relapse and no rescue therapy use during the 36-week treatment period.

Sustainability 36

Sustainability Hospital Clinic Dermatology 36

Lipgloss and Aftershave

FEBRUARY 21, 2025

This article will explore the key developments in the use of dermal fillers, including the trend of dissolving fillers, an emphasis on skin quality, the rise of combination treatments, and my personal experiences with innovative treatment protocols in my clinic.

Facials 52

Facials Hydration Injections Innovations 52

The Dermatology Digest

MARCH 10, 2025

The IGNITE study was a 24-week, randomized, placebo-controlled, double-blind study to assess the efficacy, safety and tolerability of rocatinlimab monotherapy every four weeks in 769 adults with moderate to severe AD, including patients previously treated with a biologic or systemic Janus kinase (JAK) inhibitor medication.

Dermatitis 36

Dermatitis Safety Office Eczema 36

Kim Gallo Esthetics

FEBRUARY 27, 2024

From futuristic at-home devices to clinics equipped with state-of-the-art machinery, technology has placed the tools for radiant skin in the hands of the many. The accessibility of tools and treatments prompts questions about their efficacy and safety, reminding us to trust professionals for guidance and comprehensive understanding.

Skincare 294

Skincare Esthetician Skincare Routine Chemical Peels 294

AAAMS

JUNE 20, 2024

This guide discusses how to network in the medical field and advance your career. Common networking opportunities include: Alumni networks: Medical students and graduates can often access an alumni network to connect with fellow students in the medical field.

Networking 52

Networking Medical Social Media Continuing Education 52

The Dermatology Digest

NOVEMBER 30, 2024

LP-310, developed by Lipella Pharmaceuticals for the treatment of oral lichen planus (OLP), is currently in Phase 2 clinical trials. Lipella has received an Investigational New Drug (IND) approval for a Phase 2a multicenter dose-escalation trial evaluating the safety and efficacy of LP-10 in subjects with symptomatic OLP.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

AAAMS

JUNE 20, 2024

This guide discusses how to network in the medical field and advance your career. Common networking opportunities include: Alumni networks: Medical students and graduates can often access an alumni network to connect with fellow students in the medical field.

Networking 52

Networking Medical Social Media Continuing Education 52

The Dermatology Digest

MARCH 18, 2024

If approved, we believe that DFD-29 will be the only oral medication to address both inflammatory lesions and erythema from rosacea, and will be a preferred treatment option by physicians and their patients to address the condition.”

Rosacea 74

Rosacea Medical Office Clinic 74

The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

West Lake Dermatology

MARCH 10, 2025

Preparing for Surgery Arrival at the Clinic Patients typically arrive at the clinic early in the morning, as Mohs surgery often takes several hours depending on how many stages are required. This initial step is essential for ensuring both patient safety and the precision of the procedure. How Long Does the Procedure Take?

Surgery 36

Surgery Scarring Clinic Injections 36

The Dermatology Digest

NOVEMBER 18, 2024

Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. ” Comprehensive results from both ICONIC-LEAD and ICONIC-TOTAL are being prepared for presentation at upcoming medical congresses and will be shared with health authorities in planned submissions. achieving PASI-90.

Safety 36

Safety Medical Innovations Dermatology 36

Alison Bladh

JANUARY 1, 2025

Medical and Cosmetic Solutions Platelet-Rich Plasma (PRP) Therapy : This treatment involves injecting your plasma into the brow area to stimulate hair growth. Dermatology Clinics. Microblading: Safety and Efficacy in Eyebrow Enhancement. Clinical and Aesthetic Dermatology. Journal of Cosmetic Dermatology.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

The Dermatology Digest

AUGUST 13, 2024

More data will be needed to define the safety profile of JAK inhibitors in Down syndrome, and we look forward to the completion of the trial and analysis of the full dataset.”

Clinic 74

Clinic Safety Dermatitis Medical 74

The Dermatology Digest

NOVEMBER 6, 2024

Providing up to $450,000 over two years, the TBA emerged as a key initiative of LRA’s newly developed Research Roadmap , a research strategy designed to integrate LRA’s efforts across all stages of lupus research, from early discovery through clinical application.

Hospital 36

Hospital Therapy Networking Management 36

The Dermatology Digest

JANUARY 22, 2025

are partnering for a clinical trial collaboration agreement to evaluate the topical application of Xyngari (formerly known as DMT310), Dermatas topical Spongilla powder, with daxibotulinumtoxinA-lanm (Daxxify), Revances botulinum toxin type A. Dermata Therapeutics, Inc. and Revance Therapeutics, Inc.

Injections 36

Injections Office Partnerships Clinic 36

The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. Ch’en, a medical student at the Albert Einstein College of Medicine in the Bronx, New York, and Peter A.

Treatments 77

Treatments Dermatitis Therapy Medical 77

The Dermatology Digest

FEBRUARY 14, 2024

“We are thankful to the patients and medical experts whose insights informed our clinical trials, which assessed nemolizumab’s ability to reduce the symptoms of itch and skin lesions. In the ARCADIA program, nemolizumab clinically improved skin lesions and rapidly improved itch and sleep disturbance.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

West Lake Dermatology

SEPTEMBER 24, 2024

In the ever-evolving world of weight loss treatments, GLP-1 agonists like semaglutide (the active ingredient in popular medications like Ozempic or Wegovy) and tirzepatide (the active ingredient in Mounjaro) have rapidly gained popularity. of their body weight over 68 weeks, compared to just 2.4% in the placebo group.

Medical 36

Medical Diet Safety Sustainability 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Whether caused by sun exposure, hormonal fluctuations, post-inflammatory responses, or genetic factors, pigmentation can present unique challenges in clinical practice. In 2016, Krystal completed her clinical doctorate in nursing practice. Tranexamic Acid in Dermatology: Current Perspectives and Clinical Outcomes. Farris, P.

Chemical Peels 52

Chemical Peels Hyperpigmentation Vitamin C Microneedling 52

The Dermatology Digest

FEBRUARY 11, 2024

A meta-analysis of 45 randomized clinical trials comprised of 12,996 patients disclosed neither an increased risk of major cardiovascular events (MACE) such as heart attack and stroke) nor of venous thromboembolic events (VTE). This particular study did not address other safety concerns, such as all-cause mortality, infections, or cancer.

Dermatology 74

Dermatology Safety Clinic Therapy 74

The Dermatology Digest

DECEMBER 13, 2024

This approval is based on positive results from the phase III ARCADIA clinical trial program which evaluated the efficacy and safety of nemolizumab in combination with background TCS, with or without TCI, versus placebo in combination with TCS, with or without TCI, in 1,728 patients aged 12 or older with moderate to severe atopic dermatitis.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

The Dermatology Digest

JANUARY 5, 2024

Journey Medical Corporation has submitted a New Drug Application (NDA) to the U.S. The NDA submission is based on positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea. DFD-29 is being developed in collaboration with Dr. Reddy’s Laboratories Ltd.

Rosacea 36

Rosacea Medical Office Clinic 36

The Dermatology Digest

FEBRUARY 8, 2024

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. We will, for sure, have new medications for chronic urticaria.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 80

Retinol Social Media Skincare Routine Skincare 80

US Dermatologt Partners

JANUARY 13, 2025

Professional acne extractions are clinical procedures where blackheads, whiteheads, and other types of blemishes are removed, during a dermatologic appointment. They also use topical and/or injected numbing medications to make the procedure more comfortable. What Are Acne Extractions?

Extractions 41

Extractions Scarring Pores Chemical Peels 41

The Dermatology Digest

SEPTEMBER 20, 2024

Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s The clinical study, which is an investigator-initiated study led by the Winship Cancer Institute of Emory University in Atlanta, GA, has been approved to enroll up to 28 U.S. patients at up to eight institutions in the U.S., Dr. Robert B.

Office 74

Office Clinic Safety Medical 74

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. Evommune’s pre-clinical data demonstrates that by blocking activation of MRGPRX2 and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases.

Safety 74

Safety Office Dermatitis Clinic 74

The Dermatology Digest

JULY 29, 2024

is initiating the Onward Phase 3 Clinical Program evaluating ESK-001, an oral tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis. Key secondary endpoints will include PASI 90, PASI 100 and sPGA 0 measured at Weeks 16 and 24, and safety and tolerability. Alumis Inc.

Clinic 36

Clinic Safety Office Treatments 36

The Dermatology Digest

OCTOBER 30, 2024

Grants of up to $35,000 will be awarded to promising projects in the field of clinical, biological or pharmacological research linked to dermatology. Ultimately, our aim is to improve public health outcomes and raise awareness about the critical importance of sun safety in our communities,” say Drs. Nahar and Huynh in a news release.

Sun Protection 36

Sun Protection Dermatology Innovations Safety 36

Academic Alliance in Dermatology

FEBRUARY 13, 2024

This is where medical-grade skincare like SkinCeuticals, ZO, Colorescience, Obagi, SkinMedica and Alastin distinctly outshine drugstore brands. Let’s explore why medical-grade skincare is the superior choice for anyone serious about their skin health. This means they can penetrate deeper into the skin, targeting concerns at their root.

Medical Grade Skincare 36

Medical Grade Skincare Medical Skincare Skin Health 36

Academic Alliance in Dermatology

FEBRUARY 13, 2024

This is where medical-grade skincare like SkinCeuticals, ZO, Colorescience, Obagi, SkinMedica and Alastin distinctly outshine drugstore brands. Let’s explore why medical-grade skincare is the superior choice for anyone serious about their skin health. This means they can penetrate deeper into the skin, targeting concerns at their root.

Medical Grade Skincare 36

Medical Grade Skincare Medical Skincare Skin Health 36

The Dermatology Digest

MARCH 5, 2024

Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the second half of 2024. .: Botox Cosmetic (Allergan), Dysport (Galderma), Jeuveau (Evolus), Xeomin (Merz Aesthetic), Daxxify (Revance), and Letybo (Hugel). and Europe.

Branding 74

Branding Injections Safety Facials 74

The Dermatology Digest

JANUARY 29, 2024

The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a parallel group, double-blind, vehicle-controlled study evaluating the safety and efficacy of Zoryve (roflumilast) foam, 0.3% Zoryve foam was well-tolerated with a favorable safety and tolerability profile.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74